Abstract
The dopaminergic system plays an important role in migraine and its clinical subtypes. Hypersensitization of dopamine receptor type 2 (DRD2) in migraine led to successful administration of receptor antagonists in antimigraine therapy. Ankyrin repeats and kinase domain containing 1 (ANKK1) gene in DRD2 loci is linked to comorbid neurological disorders. Dopamine beta hydroxylase (DBH) is responsible for maintaining dopamine-to-norepinephrine ratio implicated in migraine pathophysiology. Therefore, we aimed to look for association of functional variants in ANKK1 (rs1800497), DRD2 (rs6275 and rs1799732) and DBH (rs7239728 and rs1611115) genes with migraine susceptibility. The present study was carried out in two dependent cohorts (n primary = 208, n secondary = 127, n controls = 200). The results of the cohorts were pooled by meta-analysis using Fisher’s and Mantel–Haenszel test. Benjamini–Hochberg false discovery rate test was used to correct for multiple comparisons. Computer algorithm-based TANGO, WALTZ and LIMBO predictions were used to evaluate the effect of missense polymorphism (rs1800497). For ANKK1 polymorphism, variant genotype and allele showed significant associations with migraine risk. A significant protective effect of variant DRD2 rs6275 polymorphism was noticed. DBH rs7239728 imparted significant risk at genotypic, allelic and carrier analyses. We identified a risk haplotype in DRD2 loci. Two genotype interactions between ANKK1rs1800497 and DBHrs72393728 polymorphisms showed significant risks. The variant gene product of ANKK1 rs1800497 was predicted with decreased aggregation of ANKK1 protein. In conclusion, we identified novel genetic variants, haplotype and gene interactions in dopaminergic pathway as potential risk factors for migraine susceptibility.
Similar content being viewed by others
References
Arinami, T., Gao, M., Hamaguchi, H., & Toru, M. (1997). A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Human Molecular Genetics, 6(4), 577–582.
Asuni, C., Cherchi, A., Congiu, D., Piccardi, M. P., Del Zompo, M., & Stochino, M. E. (2007). Association study between clinical response to rizatriptan and some candidate genes. Journal of Headache and Pain, 8(3), 185–189. doi:10.1007/s10194-007-0388-5.
Baldwin, A. S., Jr. (1996). The NF-kappa B and I kappa B proteins: new discoveries and insights. Annual Review of Immunology, 14, 649–683. doi:10.1146/annurev.immunol.14.1.649.
Bontempi, S., Fiorentini, C., Busi, C., Guerra, N., Spano, P., & Missale, C. (2007). Identification and characterization of two nuclear factor-kappaB sites in the regulatory region of the dopamine D2 receptor. Endocrinology, 148(5), 2563–2570. doi:10.1210/en.2006-1618.
Cavestro, C., Rosatello, A., Marino, M. P., Micca, G., & Asteggiano, G. (2006). High prolactin levels as a worsening factor for migraine. Journal of Headache and Pain, 7(2), 83–89. doi:10.1007/s10194-006-0272-8.
Charbit, A. R., Akerman, S., & Goadsby, P. J. (2010). Dopamine: What’s new in migraine? Current Opinion in Neurology, 23(3), 275–281. doi:10.1097/WCO.0b013e3283378d5c.
Craig, S. P., Buckle, V. J., Lamouroux, A., Mallet, J., & Craig, I. W. (1988). Localization of the human dopamine beta hydroxylase (DBH) gene to chromosome 9q34. Cytogenetics and Cell Genetics, 48(1), 48–50.
Cubells, J. F., Kranzler, H. R., McCance-Katz, E., Anderson, G. M., Malison, R. T., Price, L. H., et al. (2000). A haplotype at the DBH locus, associated with low plasma dopamine beta-hydroxylase activity, also associates with cocaine-induced paranoia. Molecular Psychiatry, 5(1), 56–63.
Dichgans, M., Forderreuther, S., Deiterich, M., Pfaffenrath, V., & Gasser, T. (1998). The D2 receptor NcoI allele: Absence of allelic association with migraine with aura. Neurology, 51(3), 928.
Duan, J., Wainwright, M. S., Comeron, J. M., Saitou, N., Sanders, A. R., Gelernter, J., et al. (2003). Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Human Molecular Genetics, 12(3), 205–216.
Fernandez, F., Colson, N., Quinlan, S., MacMillan, J., Lea, R. A., & Griffiths, L. R. (2009). Association between migraine and a functional polymorphism at the dopamine beta-hydroxylase locus. Neurogenetics, 10(3), 199–208. doi:10.1007/s10048-009-0176-2.
Fernandez, F., Lea, R. A., Colson, N. J., Bellis, C., Quinlan, S., & Griffiths, L. R. (2006). Association between a 19 bp deletion polymorphism at the dopamine beta-hydroxylase (DBH) locus and migraine with aura. Journal of the Neurological Sciences, 251(1–2), 118–123. doi:10.1016/j.jns.2006.09.013.
Fiorentini, C., Guerra, N., Facchetti, M., Finardi, A., Tiberio, L., Schiaffonati, L., et al. (2002). Nerve growth factor regulates dopamine D(2) receptor expression in prolactinoma cell lines via p75(NGFR)-mediated activation of nuclear factor-kappaB. Molecular Endocrinology, 16(2), 353–366.
Garrido, E., Palomo, T., Ponce, G., Garcia-Consuegra, I., Jimenez-Arriero, M. A., & Hoenicka, J. (2011). The ANKK1 protein associated with addictions has nuclear and cytoplasmic localization and shows a differential response of Ala239Thr to apomorphine. Neurotoxicity Research, 20(1), 32–39. doi:10.1007/s12640-010-9219-6.
Gotoh, F., Kanda, T., Sakai, F., Yamamoto, M., & Takeoka, T. (1976). Serum dopamine-beta-hydroxylase activity in migraine. Archives of Neurology, 33(9), 656–657.
Grandy, D. K., Litt, M., Allen, L., Bunzow, J. R., Marchionni, M., Makam, H., et al. (1989). The human dopamine D2 receptor gene is located on chromosome 11 at q22–q23 and identifies a TaqI RFLP. American Journal of Human Genetics, 45(5), 778–785.
Huang, W., Payne, T. J., Ma, J. Z., Beuten, J., Dupont, R. T., Inohara, N., et al. (2009). Significant association of ANKK1 and detection of a functional polymorphism with nicotine dependence in an African-American sample. Neuropsychopharmacology, 34(2), 319–330. doi:10.1038/npp.2008.37.
Jonsson, E. G., Nothen, M. M., Neidt, H., Forslund, K., Rylander, G., Mattila-Evenden, M., et al. (1999). Association between a promoter polymorphism in the dopamine D2 receptor gene and schizophrenia. Schizophrenia Research, 40(1), 31–36.
Kelly, A. M., Ardagh, M., Curry, C., D’Antonio, J., & Zebic, S. (1997). Intravenous chlorpromazine versus intramuscular sumatriptan for acute migraine. Journal of Accident and Emergency Medicine, 14(4), 209–211.
Launer, L. J., Terwindt, G. M., & Ferrari, M. D. (1999). The prevalence and characteristics of migraine in a population-based cohort: the GEM study. Neurology, 53(3), 537–542.
Lea, R. A., Dohy, A., Jordan, K., Quinlan, S., Brimage, P. J., & Griffiths, L. R. (2000). Evidence for allelic association of the dopamine beta-hydroxylase gene (DBH) with susceptibility to typical migraine. Neurogenetics, 3(1), 35–40.
Martinez, F., Castillo, J., Pardo, J., Lema, M., & Noya, M. (1993). Catecholamine levels in plasma and CSF in migraine. Journal of Neurology, Neurosurgery and Psychiatry, 56(10), 1119–1121.
Maude, S., Curtin, J., Breen, G., Collier, D., Russell, G., Shaw, D., et al. (2001). The -141C Ins/Del polymorphism of the dopamine D2 receptor gene is not associated with either migraine or Parkinson’s disease. Psychiatric Genetics, 11(1), 49–52.
McCarthy, L. C., Hosford, D. A., Riley, J. H., Bird, M. I., White, N. J., Hewett, D. R., et al. (2001). Single-nucleotide polymorphism alleles in the insulin receptor gene are associated with typical migraine. Genomics, 78(3), 135–149. doi:10.1006/geno.2001.6647.
Michaely, P., Tomchick, D. R., Machius, M., & Anderson, R. G. (2002). Crystal structure of a 12 ANK repeat stack from human ankyrinR. EMBO Journal, 21(23), 6387–6396.
Miller, S. A., Dykes, D. D., & Polesky, H. F. (1988). A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Research, 16(3), 1215.
Neville, M. J., Johnstone, E. C., & Walton, R. T. (2004). Identification and characterization of ANKK1: A novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Human Mutation, 23(6), 540–545. doi:10.1002/humu.20039.
O’Connor, D. T., Cervenka, J. H., Stone, R. A., Levine, G. L., Parmer, R. J., Franco-Bourland, R. E., et al. (1994). Dopamine beta-hydroxylase immunoreactivity in human cerebrospinal fluid: Properties, relationship to central noradrenergic neuronal activity and variation in Parkinson’s disease and congenital dopamine beta-hydroxylase deficiency. Clinical Science (London), 86(2), 149–158.
Peroutka, S. J., Price, S. C., Wilhoit, T. L., & Jones, K. W. (1998). Comorbid migraine with aura, anxiety, and depression is associated with dopamine D2 receptor (DRD2) NcoI alleles. Molecular Medicine, 4(1), 14–21.
Prasad, P., Ambekar, A., & Vaswani, M. (2010). Dopamine D2 receptor polymorphisms and susceptibility to alcohol dependence in Indian males: A preliminary study. BMC Medical Genetics, 11, 24. doi:10.1186/1471-2350-11-24.
Rebaudengo, N., Rainero, I., Parziale, A., Rosina, F., Pavanelli, E., Rubino, E., et al. (2004). Lack of interaction between a polymorphism in the dopamine D2 receptor gene and the clinical features of migraine. Cephalalgia, 24(6), 503–507. doi:10.1111/j.1468-2982.2004.00689.x.
Tak, P. P., & Firestein, G. S. (2001). NF-kappaB: A key role in inflammatory diseases. Journal of Clinical Investigation, 107(1), 7–11. doi:10.1172/JCI11830.
Tang, Y. L., Epstein, M. P., Anderson, G. M., Zabetian, C. P., & Cubells, J. F. (2007). Genotypic and haplotypic associations of the DBH gene with plasma dopamine beta-hydroxylase activity in African Americans. European Journal of Human Genetics, 15(8), 878–883. doi:10.1038/sj.ejhg.5201838.
The International Classification of Headache Disorders: 2nd edition (2004). Cephalalgia, 24(Suppl 1), 9–160.
Todt, U., Netzer, C., Toliat, M., Heinze, A., Goebel, I., Nurnberg, P., et al. (2009). New genetic evidence for involvement of the dopamine system in migraine with aura. Human Genetics, 125(3), 265–279. doi:10.1007/s00439-009-0623-z.
Weinshilboum, R., & Axelrod, J. (1971). Serum dopamine-beta-hydroxylase activity. Circulation Research, 28(3), 307–315.
Yealy, D. M. (1994). Acute pain management. Academic Emergency Medicine, 1(2), 186–189.
Acknowledgments
This work was supported by Indian Council of Medical Research (ICMR) [Number 54/6/2006-BMS] and Council of Scientific and Industrial Research (CSIR) [File number 09/590(0141)/2008-EMR-I], New Delhi, India.
Ethics statement
The study protocol was approved by the Institutional ethical committee of SGPGIMS, Lucknow (India), and has therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki. All persons gave their informed consent prior to their inclusion in the study.
Conflict of interest
The authors declare that there is no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ghosh, J., Pradhan, S. & Mittal, B. Identification of a Novel ANKK1 and Other Dopaminergic (DRD2 and DBH) Gene Variants in Migraine Susceptibility. Neuromol Med 15, 61–73 (2013). https://doi.org/10.1007/s12017-012-8195-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12017-012-8195-9